The AAAAI allergy and asthma medication guide is a widely referenced international resource, but patients in the UK should understand how these treatments align with NHS, NICE, and MHRA guidance. Allergy and asthma affect millions across the United Kingdom, encompassing conditions such as hay fever, allergic rhinitis, eczema, and allergic asthma. This guide explains the full range of UK-licensed medications available — from reliever inhalers and antihistamines to biologics and allergen immunotherapy — covering how they work, how they are prescribed on the NHS, their safety profiles, and when to seek urgent medical advice.

Understanding Allergy and Asthma Medications Available in the UK

A broad range of UK-licensed medications is available for allergy and asthma, including bronchodilators, inhaled corticosteroids, antihistamines, biologics, and allergen immunotherapy, governed by NHS, NICE, MHRA, and BSACI guidance.

Allergy and asthma are closely related conditions that affect millions of people across the United Kingdom. Allergic conditions — including hay fever, allergic rhinitis, eczema, food allergies, and allergic asthma — arise when the immune system mounts an exaggerated response to otherwise harmless substances known as allergens. Asthma, characterised by airway inflammation, bronchoconstriction, and mucus production, is frequently triggered or worsened by allergic sensitisation.

In the UK, a broad range of medications is available to manage these conditions, spanning both prescription-only medicines and over-the-counter (OTC) products. These include:

• Bronchodilators (short- and long-acting) to relieve and prevent airway narrowing

• Inhaled corticosteroids (ICS) to reduce airway inflammation

• Long-acting muscarinic antagonists (LAMAs) and single-inhaler triple therapies (ICS/LABA/LAMA) for add-on management of uncontrolled asthma

• Antihistamines to control allergic symptoms such as sneezing, itching, and urticaria

• Intranasal corticosteroids for allergic rhinitis

• Leukotriene receptor antagonists (LTRAs) for both asthma and allergic rhinitis

• Biologics for severe, refractory disease, initiated under specialist care in line with NICE Technology Appraisals

• Allergen immunotherapy (subcutaneous [SCIT] or sublingual [SLIT]) for eligible patients with allergic rhinitis or venom allergy, delivered via specialist services

• Adrenaline auto-injectors (e.g., EpiPen, Jext) for patients at risk of anaphylaxis

Whilst organisations such as the American Academy of Allergy, Asthma and Immunology (AAAAI) provide internationally recognised educational resources, patients in the UK should primarily follow advice from the NHS, the National Institute for Health and Care Excellence (NICE), the Medicines and Healthcare products Regulatory Agency (MHRA), and the British Society for Allergy and Clinical Immunology (BSACI). UK-licensed medications may differ in availability, formulation, or approved indications compared with those in other countries, so it is important to consult a UK-registered healthcare professional for personalised advice.

How Allergy and Asthma Treatments Are Prescribed on the NHS

NHS allergy and asthma treatments are prescribed via a stepped-care model, starting with GP assessment; complex or severe cases are referred to specialist or tertiary care, including Severe Asthma Network UK centres.

In England, Wales, Scotland, and Northern Ireland, allergy and asthma treatments are typically initiated and reviewed by GPs, practice nurses, or specialist clinicians such as respiratory physicians, allergists, and immunologists. The NHS operates a stepped-care model for asthma management, meaning treatment is escalated or de-escalated based on symptom control, exacerbation frequency, and objective lung function measurements.

For most patients, the journey begins with a GP consultation. Following a clinical assessment — which may include spirometry, bronchodilator reversibility testing, fractional exhaled nitric oxide (FeNO) measurement, or peak flow monitoring — an appropriate treatment plan is formulated in line with NICE NG80. In primary care, allergy investigation typically involves specific IgE blood tests; allergy skin-prick testing is generally performed in specialist allergy clinics rather than routine general practice. Prescriptions for standard medications such as short-acting beta-2 agonists (SABAs), inhaled corticosteroids, and antihistamines are routinely issued in primary care. More complex cases — including those with severe or difficult-to-treat asthma, anaphylaxis risk, or multiple allergic comorbidities — are referred to secondary or tertiary care, including Severe Asthma Network UK (SANUK) centres where appropriate.

Key points about NHS prescribing include:

• Prescription charges apply in England; the current charge is subject to periodic review — visit the NHS website (nhs.uk/nhs-services/prescriptions-and-pharmacies) for up-to-date figures and exemption criteria

• Scotland, Wales, and Northern Ireland provide free NHS prescriptions

• Specialist referral is recommended when standard treatments fail to achieve adequate control, when severe asthma is suspected, or when a biologic therapy is being considered

• Shared decision-making is central to NHS prescribing, ensuring patients understand their treatment options, inhaler technique, and self-management strategies

Patients are encouraged to use NHS-approved resources such as the Asthma + Lung UK helpline and NICE patient decision aids to support informed choices about their care.

Common Medications Used to Manage Allergies and Asthma

UK allergy and asthma management uses multiple drug classes including SABAs, ICS, LTRAs, LABAs, LAMAs, antihistamines, intranasal corticosteroids, biologics, and allergen immunotherapy, each targeting different aspects of the disease.

A variety of medication classes are used in the UK to manage allergic and asthmatic conditions. Understanding how each works helps patients engage more effectively with their treatment plans.

Short-Acting Beta-2 Agonists (SABAs) — such as salbutamol (Ventolin) — act by relaxing bronchial smooth muscle through stimulation of beta-2 adrenoceptors, providing rapid relief of bronchoconstriction. They are used as reliever inhalers. Needing a reliever inhaler three or more times a week is a sign that asthma is not well controlled and warrants clinical review.

Inhaled Corticosteroids (ICS) — such as beclometasone, budesonide, and fluticasone — are the cornerstone of preventer therapy. They reduce airway inflammation by suppressing the release of inflammatory mediators, thereby decreasing exacerbation risk and improving lung function over time.

Leukotriene Receptor Antagonists (LTRAs) — such as montelukast — are often the first add-on therapy to low-dose ICS in adults and children, as recommended by NICE NG80. They block the action of leukotrienes, inflammatory mediators involved in both asthma and allergic rhinitis, and are particularly useful in patients with both conditions concurrently.

Long-Acting Beta-2 Agonists (LABAs) — such as salmeterol and formoterol — are used in combination with ICS (never alone in asthma) to provide sustained bronchodilation. Fixed-dose combination inhalers (e.g., Seretide, Fostair, Symbicort) simplify regimens and improve adherence. For eligible patients, NICE NG80 supports MART (Maintenance and Reliever Therapy) regimens using a single ICS/formoterol inhaler for both daily preventer use and as-needed relief.

Long-Acting Muscarinic Antagonists (LAMAs) — such as tiotropium — may be added as further add-on therapy for patients whose asthma remains uncontrolled on ICS/LABA. Single-inhaler triple therapy (ICS/LABA/LAMA) is available for appropriate patients and is initiated under specialist guidance.

Antihistamines — both sedating (e.g., chlorphenamine) and non-sedating (e.g., cetirizine, loratadine, fexofenadine) — block H1 histamine receptors to relieve sneezing, rhinorrhoea, urticaria, and itching. Non-sedating antihistamines are generally preferred for daytime use.

Intranasal corticosteroids — such as fluticasone nasal spray and mometasone — are first-line treatments for persistent or moderate-to-severe allergic rhinitis, reducing nasal inflammation effectively with minimal systemic absorption. Intranasal antihistamines and combination intranasal sprays (e.g., azelastine with fluticasone) are also available and may offer faster symptom relief. Topical nasal decongestants should be used for no more than a few days to avoid rebound congestion (rhinitis medicamentosa).

Biologics — including omalizumab (anti-IgE), mepolizumab, benralizumab, reslizumab, dupilumab, and tezepelumab — are reserved for severe, treatment-resistant disease and are initiated only by specialists in line with relevant NICE Technology Appraisals. The choice of biologic depends on the patient's inflammatory phenotype (e.g., IgE-mediated, eosinophilic, or type-2 driven disease). Some biologics are also licensed for conditions such as chronic rhinosinusitis with nasal polyps or atopic dermatitis.

Allergen immunotherapy (AIT) — delivered as subcutaneous injections (SCIT) or sublingual tablets or drops (SLIT) — is available through specialist allergy services for eligible patients with allergic rhinitis (including hay fever) or insect venom allergy. AIT aims to modify the underlying allergic response rather than simply relieving symptoms, and referral to a BSACI-accredited centre is required.

Potential Side Effects and Safety Considerations

Key safety concerns include oral candidiasis with ICS, neuropsychiatric effects with montelukast (MHRA 2019 warning), sedation with first-generation antihistamines, and injection-site reactions with biologics.

All medications carry the potential for side effects, and allergy and asthma treatments are no exception. Being aware of common and serious adverse effects enables patients to monitor their health and seek timely advice.

Inhaled corticosteroids, whilst generally well tolerated, can cause local side effects including oral candidiasis (thrush) and dysphonia (hoarseness). Using a spacer device and rinsing the mouth after each dose significantly reduces these risks. At high doses, systemic effects such as adrenal suppression, reduced bone density, and growth retardation in children may occur; the MHRA has issued safety guidance on these risks. Patients taking high-dose ICS should be monitored accordingly. Fluticasone propionate and other ICS metabolised via CYP3A4 can interact with certain medicines — always inform your GP or pharmacist of all medications you are taking.

SABAs, when overused, may cause tremor, palpitations, and hypokalaemia (low potassium). Needing a reliever inhaler three or more times a week indicates poorly controlled asthma and warrants clinical review.

Antihistamines — particularly first-generation agents such as chlorphenamine — can cause significant sedation, impaired cognitive function, and anticholinergic effects (dry mouth, urinary retention, constipation). Patients should be advised not to drive or operate machinery if affected.

Montelukast carries an MHRA warning regarding neuropsychiatric side effects, including sleep disturbances, nightmares, anxiety, depression, and suicidal ideation. The MHRA issued a Drug Safety Update on this in 2019, with subsequent reminders. Patients and carers should be counselled about these risks before initiation, and the medication should be stopped and medical advice sought if such symptoms emerge.

Biologics may cause injection-site reactions and, rarely, hypersensitivity reactions. After initiation and an appropriate period of supervised monitoring, several biologic agents are suitable for home self-injection by trained patients or carers, in accordance with the relevant product SmPC and NICE Technology Appraisal. Your specialist team will advise on the most appropriate approach for your treatment.

Key safety considerations across all treatments include:

• Always carry an adrenaline auto-injector (e.g., EpiPen, Jext) if prescribed for anaphylaxis risk, and ensure it is in date

• Never stop preventer inhalers abruptly without medical advice

• Inform your GP or pharmacist of all medications, including OTC products and supplements, to avoid interactions

• Report any suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk — your report contributes to ongoing medicine safety monitoring

When to Seek Medical Advice About Your Treatment

Contact your GP if you need a reliever inhaler three or more times a week or symptoms disturb sleep; call 999 immediately for severe asthma attacks or signs of anaphylaxis.

Knowing when to contact a healthcare professional is a vital component of safe self-management for allergy and asthma. Whilst many symptoms can be managed at home with prescribed treatments, certain signs indicate that urgent or prompt medical attention is required.

Contact your GP or asthma nurse if:

• Your reliever inhaler is needed three or more times a week

• Symptoms are waking you at night

• Your peak flow readings are consistently below your personal best, or fall below 50% of your best or expected value

• You have needed oral corticosteroids more than twice in the past year

• You experience new or worsening side effects from your medication

• Allergy symptoms are not adequately controlled despite treatment

Seek urgent medical attention (call 999 or go to A&E) if:

• You experience a severe asthma attack — key warning signs include inability to speak in full sentences, breathing very fast, or feeling exhausted from the effort of breathing

• Your peak flow falls below 50% of your best or expected value and does not improve with your reliever inhaler

• Your reliever inhaler provides no relief or its effect is very short-lived

• You develop signs of anaphylaxis — including throat swelling, difficulty breathing, a sudden drop in blood pressure, or loss of consciousness

If anaphylaxis is suspected: use your adrenaline auto-injector immediately into the outer thigh, call 999, and lie flat with your legs raised (unless breathing is difficult, in which case sit up). If there is no improvement after five minutes, use a second adrenaline auto-injector if available. Follow the Resuscitation Council UK guidance on emergency treatment of anaphylaxis.

Patients with asthma should have a written Personal Asthma Action Plan (PAAP), developed with their GP or nurse, which outlines what to do when symptoms worsen. Annual asthma reviews are recommended by NICE and should include inhaler technique assessment, adherence review, and trigger identification. Those with known severe allergies should ensure their adrenaline auto-injector is in date, accessible at all times, and that those around them know how to use it.

NICE and MHRA Guidance on Allergy and Asthma Management

NICE NG80 sets out a stepwise asthma treatment pathway, while the MHRA issues Drug Safety Updates on risks such as montelukast's neuropsychiatric effects and systemic corticosteroid side effects.

In the UK, clinical practice for allergy and asthma management is shaped primarily by guidance from NICE and safety communications from the MHRA, ensuring treatments are evidence-based, safe, and cost-effective.

NICE guidance on asthma (NG80) recommends a structured, stepwise approach to treatment. The current live version of NG80 should be consulted at nice.org.uk for the most up-to-date recommendations. Key principles include:

• Confirming asthma diagnosis objectively using spirometry and bronchodilator reversibility testing, or fractional exhaled nitric oxide (FeNO) measurement — a FeNO level of 40 ppb or above in adults (35 ppb or above in children) supports a diagnosis of eosinophilic airway inflammation

• Initiating a low-dose ICS as the first preventer therapy in adults and children over five

• Offering a leukotriene receptor antagonist (LTRA) as the initial add-on to low-dose ICS before considering a LABA, in line with the NICE NG80 treatment ladder

• Adding a LABA (always in combination with ICS) at the next step if an LTRA alone is insufficient

• Considering MART (Maintenance and Reliever Therapy) regimens using a single ICS/formoterol inhaler for eligible patients, as an alternative to separate preventer and reliever inhalers

• Referring to specialist care when asthma remains uncontrolled at higher treatment steps, or when severe asthma or biologic therapy is being considered

For allergic rhinitis, NICE Clinical Knowledge Summaries recommend intranasal corticosteroids as first-line treatment for persistent or moderate-to-severe symptoms, with antihistamines suitable for mild or intermittent disease.

The MHRA regularly issues Drug Safety Updates relevant to allergy and asthma. Notable communications include the neuropsychiatric risk associated with montelukast (2019 and subsequent reminders) and guidance on the systemic effects of inhaled and intranasal corticosteroids at higher doses.

Guidance on the environmental impact of inhalers — including the encouragement to consider dry powder inhalers (DPIs) or low-global-warming-potential pressurised metered-dose inhalers (pMDIs) where clinically appropriate — comes from NHS England and NICE (including the NICE patient decision aid on inhalers for asthma), as part of the NHS's net-zero carbon commitment. Inhaler choice should always be made on clinical grounds first, in shared discussion with the patient.

Patients and clinicians are encouraged to report suspected adverse drug reactions via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk), which plays a crucial role in ongoing post-market surveillance. Staying informed through NHS, NICE, MHRA, and BSACI resources ensures that allergy and asthma management remains aligned with the best available evidence.

Frequently Asked Questions